pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-6-112-116pulmo-319Research ArticleЗАМЕТКИ ИЗ ПРАКТИКИPRACTICAL NOTESКомбинированная терапия ингаляционным илопростом и бозентаном у больной идиопатической легочной гипертензиейTherapy of idiopathic pulmonary hypertension with combination of inhaled iloprost and bosentanАвдеевС. Н.AvdeevS. N.

д. м. н., профессор, руководитель клинического отдела 

105077, Россия, Москва, ул. 11-я Парковая, 32, корп. 4. Тел. / факс: (495) 465-52-64.

serg_avdeev@list.ruЦареваН. А.TsarevaN. A.

к. м. н., заведующий лаборатории интенсивной пульмонологии и дыхательной недостаточности

105077, Россия, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-74-15.

n_tsareva@mail.ruНеклюдоваГ. В.NekludovaG. V.

д. м. н., ведущий научный сотрудник лаборатории функциональных методов исследования 

105077, Россия, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-53-84.

nekludova_gala@mail.ruФБГУ "НИИ пульмонологии" ФМБА РоссииRussian Federation20132812201306112116Copyright © Авдеев С.Н., Царева Н.А., Неклюдова Г.В., 20132013Авдеев С.Н., Царева Н.А., Неклюдова Г.В.Avdeev S.N., Tsareva N.A., Nekludova G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/319

Комбинированная терапия ингаляционным илопростом и бозентаном у больной идиопатической легочной гипертензией.

Therapy of idiopathic pulmonary hypertension with combination of inhaled iloprost and bosentan.

идиопатическая легочная артериальная гипертензиякомбинированная терапияингаляционный илопростбозентанidiopathic pulmonary hypertensioncombined therapyinhaled iloprostbosentanReferencesGalié N., Hoeper M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart. J. 2009; 30: 2493–2537.Galié N., Hoeper M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart. J. 2009; 30: 2493–2537.Galié N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219–1263.Galié N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219–1263.McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF / AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250–2294.McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF / AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250–2294.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023–1030.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023–1030.Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30: 104–109.Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30: 104–109.Badesch B.D., Champion H.C., Gomez7Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54: S55–S56.Badesch B.D., Champion H.C., Gomez7Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54: S55–S56.Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.Thenappan T., Shah S.J., Rich S. et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 2010; 35: 1079–1087.Thenappan T., Shah S.J., Rich S. et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 2010; 35: 1079–1087.Tyndall A.J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 2010; 69: 1809–1815.Tyndall A.J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 2010; 69: 1809–1815.Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996; 334: 296–302.Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996; 334: 296–302.McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 2006; 36 (Suppl. 13): 10–15.McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 2006; 36 (Suppl. 13): 10–15.Sitbon O., McLaughlin V.V., Badesch D.B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025–1030.Sitbon O., McLaughlin V.V., Badesch D.B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025–1030.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346: 896–903.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346: 896–903.Barst R.J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 441–447.Barst R.J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 441–447.Barst R.J., Langleben D., Badesch D. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 2006; 47: 2049–2056.Barst R.J., Langleben D., Badesch D. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 2006; 47: 2049–2056.Galié N., Ghofrani H.A., Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005; 353: 2148–2157.Galié N., Ghofrani H.A., Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005; 353: 2148–2157.Galié N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.Galié N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.Galié N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.Galié N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.Galié N., Rubin L.J., Hoeper M.M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.Galié N., Rubin L.J., Hoeper M.M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты 1-годичного исследования. Тер. арх. 2013; 3: 38–43.Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты 1-годичного исследования. Тер. арх. 2013; 3: 38–43.Galié N., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. 2004; 25: 2243–2278.Galié N., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. 2004; 25: 2243–2278.Badesch D.B., Abman S.H., Ahearn G.S. et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004; 126 (Suppl. 1): 35S–62S.Badesch D.B., Abman S.H., Ahearn G.S. et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004; 126 (Suppl. 1): 35S–62S.Badesch D.B., Abman S.H., Simonneau G. et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917–1928.Badesch D.B., Abman S.H., Simonneau G. et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917–1928.Frishman W.H., Landau A., Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J. Clin. Pharmacol. 1993; 33: 752–755.Frishman W.H., Landau A., Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J. Clin. Pharmacol. 1993; 33: 752–755.Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709–717.Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709–717.Humbert M., Barst R.J., Robbins I.M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24: 353–359.Humbert M., Barst R.J., Robbins I.M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24: 353–359.Hoeper M.M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28: 691–694.Hoeper M.M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28: 691–694.Simonneau G., Rubin L.J., Galiè N. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 2008; 149: 521–530.Simonneau G., Rubin L.J., Galiè N. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 2008; 149: 521–530.McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174: 1257–1263.McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2006; 174: 1257–1263.

The authors declare that there are no conflicts of interest present.